Theoretical Arguments for the Discounting of Health Consequences: Where Do We Go from Here?

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.20, Iss.14, 2002-01, pp. : 943-961

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Therapy for Osteosarcoma: Where Do We Go From Here?

By Chou Alexander J.

Pediatric Drugs, Vol. 10, Iss. 5, 2008-01 ,pp. : 315-327

Adis International

Access to resources Recommend Favorite

Phosphodiesterase 4 Inhibitors and the Treatment of Asthma: Where Are We Now and Where Do We Go from Here?

By Giembycz M.A.

Drugs, Vol. 59, Iss. 2, 2000-02 ,pp. : 193-212

Adis International

Access to resources Recommend Favorite

Supplementary protection certificates on reformulations and new uses after Neurim: where do we go from here?

By Duncan Garreth

Pharmaceutical Patent Analyst, Vol. 2, Iss. 2, 2013-03 ,pp. : 157-159

Future Science

Access to resources Recommend Favorite

Tamoxifen for breast cancer prophylaxis: where to from here?

Inpharma, Vol. 1, Iss. 1219, 2000-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Acetaminophen safety and hepatotoxicity – where do we go from here?

By Amar Patrick J Schiff Eugene R

Expert Opinion on Drug Safety, Vol. 6, Iss. 4, 2007-07 ,pp. : 341-355

Informa Healthcare

Access to resources Recommend Favorite